Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix President Andrew Uprichard: An Interview With "The Pink Sheet" DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

A day after Epix announces plans to further appeal two FDA "approvable" letters for Vasovist, Uprichard discusses why he's taking his case to CDER Director Steve Galson.

You may also be interested in...



Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY

Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.

Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY

Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.

Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin

Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel